ClinicalTrials.gg
CompletedNCT07279233Updated May 8, 2026

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

A Phase 1 interventional study of Mirdametinib and Mirdametinib and Carbamazepine in Healthy and Volunteer, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of carbamazepine on the blood levels of mirdametinib and how long it takes the body to eliminate mirdametinib when both drugs are administered orally in healthy participants. The study may last up to approximately 64 days for each participant.

Read the detailed description

This is a Phase 1, open-label, fixed-sequence, 2-period clinical study in healthy participants. Approximately 36 participants will be enrolled in the study to achieve 25 evaluable participants.

Healthy male and/or female participants, aged 18 to 65 years (inclusive), not of Asian descent, with body mass index (BMI) between 18 and 32 kg/m², and who are medically healthy with no clinically significant abnormalities.

The study consists of screening (28 days), 2 study periods, and a 7-day follow-up.

Mirdametinib will be given as a single 6-mg dose on 2 separate occasions: once on Day 1 and once on Day 22. Carbamazepine ER will be given twice daily for 21 days beginning on Day 8.

On Day 1 of Period 1, participants will receive a 6-mg single oral dose of mirdametinib followed by PK sampling for 168 hours (Day 8). In Period 2, participants will receive carbamazepine extended-release (ER) twice daily for 21 days with a titration schedule (100 mg twice daily [BID] for 2 days, 200 mg BID for 2 days, and 300 mg BID for the remaining days). On Day 22, participants will receive a 6-mg single dose of mirdametinib with the morning dose of carbamazepine ER, followed by PK sampling for 168 hours.

02

Conditions studied

  • Healthy
  • Volunteer

Keywords

  • Drug interaction
  • Mirdametinib
  • Carbamazepine
03

In context

Lead sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must sign the form (ICF) prior to any study-related procedures being performed.
  2. Participant is male or female and between 18 and 65 years of age (inclusive) at the time of informed consent.
  3. Participant has a (BMI) ≥18 and ≤32 kg/m² (inclusive) at Screening and Day -1.
  4. Participant is in good health in the judgment of the investigator on the basis of a medical evaluation performed at Screening, Day -1, and predose on Day 1, and the results of clinical chemistry, hematology, coagulation, and urinalysis tests carried out at Screening and Day -1. Clinical laboratory test results within normal reference range for the population or investigative site, or results within acceptable deviations that are judged to be not by the investigator.

    Note: Laboratory values that are out-of-range may be confirmed by a single repeat per investigator discretion.

  5. Participant has normal or mildly impaired renal function as estimated by the Chronic Kidney Disease Epidemiology Collaboration formula (i.e., ≥60 mL/min).
  6. Participant has sufficiently good venous access in at least 1 arm to confidently enable serial blood sampling.
  7. Male participants who agree to the following during study and for at least 90 days after the last dose of study medication:

    1. Refrain from donating or preserving sperm, PLUS either
    2. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR
    3. Must agree to use a male condom when having sexual intercourse with women of (WOCBP). An additional form of should also be used by the female partner if she is of childbearing potential.
  8. Female participants that are not pregnant or breastfeeding, and for whom one of the following conditions applies:

    1. Is a woman of non-childbearing potential.
    2. Is a WOCBP and agrees to use an acceptable contraceptive method from the time of signed informed consent and for at least 6 weeks after the last dose of study medication; AND
  9. All female participants must have a negative serum pregnancy test at Screening and CRU admission (Day -1)

Exclusion criteria

Exclusion Criteria:

  • Participant has infections (e.g., coronavirus disease 2019 [COVID-19] or influenza) within 90 days prior to Day 1, as judged by the investigator, or evidence of any infection within 14 days prior to Day 1. If a participant tests positive (reactive) for , , or at Screening, they are not eligible for participation in the study.

    2. Participant has a history of any neurological conditions including movement disorders and seizures.

    3. Participant has a history of stomach or GI surgery or resection that would potentially alter absorption, metabolism, and/or excretion of PO administered drugs (exceptions include participants who underwent appendectomy or any type of hernia repair).

    4. Participant has a history of pre-existing condition interfering with normal GI anatomy or motility and potentially alter the absorption, metabolism, and/or excretion of orally administered drugs.

    5. Participants with a history of inflammatory bowel disease, peptic ulceration, or pancreatitis within 180 days prior to Day 1.

    6. Participant has a history of cancer, except if judged to be in full remission for at least 5 years at the time of (except basal cell skin cancer, resected prostate cancer with an undetectable Prostate-Specific Antigen test (PSA), or squamous cell skin cancer with history of curative treatment and no recurrence for at least 3 years prior to Screening), as judged by the investigator.

    7. Participant has an acute illness with symptoms or treatment that has started or persisted within 14 days prior to Day 1 unless mild in severity and enrollment is approved by both the investigator and the sponsor's medical monitor.

    8. Participant has any evidence of glaucoma or retinal vein occlusion, visual blurring or uncorrected vision issues, or intraocular pressure (IOP) >21 mmHg on Day -1.

    9. Participant has cardiovascular abnormalities including:

    1. History of postural hypotension, unexplained syncope, or abnormal autonomic tone
    2. Blood pressure \<90/50 mmHg or >140/90 mmHg after 5 minutes of rest
    3. Heart rate \<45 or >100 bpm after 5 minutes of rest
    4. Abnormal corrected by Fridericia's formula (QTcF) interval (≥450 msec) or abnormalities interfering with QT/QTc interpretation
    5. Risk factors for torsades de pointes
    6. \<55% 10. Participant has an acute illness, significant infection, or incomplete bladder emptying (voiding >2 times/night).

      11. Participant has any clinically significant abnormality in hematology parameters at Screening or Day -1 as determined by the investigator.

    <!-- -->

    1. Participant has a \< 11.0 g/dL for female participants or \< 12.5 g/dL for male participants.
    2. Participant has a hematocrit \< the lower limit of normal.
    3. Participant has a white blood cell count \< the lower limit of normal.
    4. Participant has a count \< the lower limit of normal. 12. Participant has a history or evidence of any hematological disorder such as anemia, leukopenia, thrombocytopenia, or bleeding disorder.

      13. Participant has any known or suspected hereditary blood disorder (e.g., sickle cell, or thalassemia).

      14. Participant has , aspartate aminotransferase, alkaline phosphatase, or total levels >1.5× the at Screening or Day -1.

      15. Participant has substance use concerns:

    <!-- -->

    1. Positive alcohol, cotinine, or drug screen test
    2. Alcohol intake >3 units/day or >14 units/week in past 6 months
    3. Excessive caffeine consumption (>400 mg/day)
    4. Tobacco or nicotine use within 3 months of Screening
    5. Unwillingness to avoid xanthine-containing products 72 hours before dosing 16. Participant has taken, received, or consumed:

    <!-- -->

    1. Any prescription medications, over-the-counter medications, supplements, or herbal products within 28 days or 5 half-lives if known (whichever is longer)
    2. Vaccines within 14 days prior to Day 1; within 28 days prior to Day 1.c. products within 28 days or 5 half-lives, or >3 new investigational entities within 12 months

    d. Red wine, any fruit juices (including, but not limited to, grapefruit, grapefruit juice, pomelos, or other exotic citrus fruits, or grapefruit hybrids), or any nutrients known to modulate drug metabolizing enzyme/transporters activity (including, but not limited to, cranberries or star fruits) within 72 hours of Day -1 17. Participant has donated blood (>450 mL) within 60 days, donated plasma within 7 days, or received blood products within 60 days.

    18. Participant is unwilling to avoid strenuous activity, sunbathing, or contact sports during the study.

    19. Participant has a history of known prior major depression. 20. Participant has a significant risk of committing suicide based on medical history in the opinion of the investigator; or an answer of "Yes" to questions #4 or #5 of the Columbia-Suicide Severity Scale (C-SSRS; [Posner 2011]).

    21. Participant has specific to the study medications:

    a. Known to carbamazepine, mirdametinib, or related compounds b. Participant is Asian or has one or more Asian parents or grandparents c. History of anaphylaxis d. History of severe cutaneous adverse reactions (such as Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug Reaction with Eosinophilia and Systemic Symptoms).

    22. Participant is deemed unsuitable for this study in the opinion of the investigator for any additional reason.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Period 1 Mirdametinib

    Mirdametinib 6-mg single dose given orally alone on Day 1 as three 2-mg capsules following a 10-hour fast.

    Drug: Mirdametinib

  • Experimental
    Period 2 Mirdametinib and carbamazepine

    Mirdametinib 6-mg single dose given orally on Day 22 in Period 2 as three 2-mg capsules following a 10-hour fast in combination with carbamazepine tablets that are administered orally according to the following schedule: * Days 8 and 9: 100 mg BID with meals * Days 10 and 11: 200 mg BID with meals * Days 12 through 21: 300 mg BID with meals * Day 22: 300 mg AM fasted, with mirdametinib, and 300 mg PM with meal * Days 23 through 28: 300 mg BID with meals * Days 29 through 30: no doses (observation only)

    Drug: Mirdametinib and Carbamazepine

Interventions

  • 6-mg single dose given orally on Day 1

  • DrugMirdametinib and Carbamazepine

    Drug pages: Mirdametinib · Carbamazepine

    Drug: Mirdametinib 6-mg single dose given orally on Day 22. Drug: Carbamazepine Carbamazepine extended-release (ER) (Carbamazepine ER will be given orally twice daily for 21 days with a titration schedule \[100 mg BID for 2 days, 200 mg BID for 2 days, and then 300 mg BID\]).

06

What researchers measure

Primary outcomes

  1. The geometric mean ratio of mirdametinib plasma area under the concentration-time curve from dosing extrapolated to infinity (AUCinf) of Mirdametinib

    Time frame: Day 1 to Day 29

  2. The geometric mean ratio area under the concentration-time curve from dosing to time of last quantifiable concentration (AUClast) of Mirdametinib

    Time frame: Day 1 to Day 29

  3. The geometric mean ratio of maximum observed concentration (Cmax) of Mirdametinib

    Time frame: Day 1 to Day 22

Secondary outcomes

  1. Number of participants who Experience an Adverse Event

    Time frame: Up to a maximum of 36 days

  2. AUCinf of Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 29

  3. AUClast of Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 29

  4. Cmax of Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 22

  5. Time of maximum observed concentration (Tmax) of Mirdametinib and Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 22

  6. Apparent terminal elimination half-life (t1/2) of Mirdametinib and Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 29

  7. Apparent clearance (CL/F) of Mirdametinib and Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 29

  8. Apparent volume of distribution (Vd/F) of Mirdametinib and Metabolites M15, M22, and M30

    Time frame: Day 1 to Day 29

  9. Metabolite to parent molar ratio AUCinf (MRAUCinf)

    (AUCinf, metabolite/MWmetabolite)/(AUCinf, parent/MWparent)

    Time frame: Day 1 to Day 29

  10. Metabolite to parent molar ratio AUClast (MRAUClast),

    (AUClast, metabolite/MWmetabolite)/(AUClast, parent/MWparent)

    Time frame: Day 1 to Day 29

  11. Metabolite to parent molar ratio Cmax (MRCmax)

    (Cmax, metabolite/MWmetabolite)/(Cmax, parent/MWparent)

    Time frame: Day 1 to Day 22

07

Study locations

1 site
  • Medpace
    Cincinnati, Ohio 45227, United States
08

References and documents

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Feb 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Dec 15, 2025
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07279233
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Dec 15, 2025
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mirdametinib · Carbamazepine

Start the discussion